Vito Lorusso1, Saverio Cinieri2, Agnese Latorre1, Luca Porcu3, Lucia Del Mastro4, Fabio Puglisi5, Sandro Barni6. 1. UOC Oncologia Medica, Istituto Tumori Giovanni Paolo II, Bari, Italy. 2. Medical Oncology Division and Breast Unit, Ospedale A Perrino, Brindisi, Italy. 3. Oncology Department, IRRCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. 4. Department of Medical Oncology, IRCCS AOU San Martino - IST, Genova, Italy. 5. Oncology Department, Azienda Ospedaliero-Universitaria di Udine, Udine, Italy. 6. Oncology Unit, Oncology Department, ASST Bergamo Ovest Ospedale, Treviglio, Bergamo, Italy.
Abstract
AIM: Recent clinical, randomized and observational studies showed that eribulin, an analogous of Halichondrin B, was beneficial and well-tolerated in heavily pretreated metastatic breast cancer patients. Here, we aim to evaluate the effectiveness and safety of eribulin in taxane-refractory metastatic breast cancer patients. PATIENTS & METHODS: In this subanalysis of the ESEMPIO study database, we selected 91 subjects with well-defined taxane refractoriness and complete data available. RESULTS: 41 patients (45.2%) showed clinical benefit; one complete response (2.2%) and 16 partial responses (17.6%) were observed. Median progression-free survival and median overall survival were 3.1 and 11.6 months, respectively. The most experienced adverse event was asthenia/fatigue (58%), followed by neutropenia (30%). The treatment-related toxicity led to eribulin-dose reduction in 19 patients and suspension in nine. CONCLUSION: This study shows that eribulin is effective and well tolerated also in taxane-refractory patients in clinical practice.
AIM: Recent clinical, randomized and observational studies showed that eribulin, an analogous of Halichondrin B, was beneficial and well-tolerated in heavily pretreated metastatic breast cancerpatients. Here, we aim to evaluate the effectiveness and safety of eribulin in taxane-refractory metastatic breast cancerpatients. PATIENTS & METHODS: In this subanalysis of the ESEMPIO study database, we selected 91 subjects with well-defined taxane refractoriness and complete data available. RESULTS: 41 patients (45.2%) showed clinical benefit; one complete response (2.2%) and 16 partial responses (17.6%) were observed. Median progression-free survival and median overall survival were 3.1 and 11.6 months, respectively. The most experienced adverse event was asthenia/fatigue (58%), followed by neutropenia (30%). The treatment-related toxicity led to eribulin-dose reduction in 19 patients and suspension in nine. CONCLUSION: This study shows that eribulin is effective and well tolerated also in taxane-refractory patients in clinical practice.
Entities:
Keywords:
eribulin; metastatic breast cancer; taxane-refractory